Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR6 | P50406 | 14/20 | 0.64 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.60 |
| ▸ | AKR1C1 | Q04828 | 1/20 | 0.60 |
| ▸ | LMNA | P02545 | 1/20 | 0.59 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.59 |
| ▸ | CA12 | O43570 | 1/20 | 0.58 |
| ▸ | CA1 | P00915 | 1/20 | 0.58 |
| ▸ | CA2 | P00918 | 1/20 | 0.58 |
| ▸ | CA9 | Q16790 | 1/20 | 0.58 |
| ▸ | PLK1 | P53350 | 1/20 | 0.55 |
| ▸ | MEN1 | O00255 | 1/20 | 0.55 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.55 |
| ▸ | HTR1A | P08908 | 2/20 | 0.54 |
| ▸ | DRD2 | P14416 | 2/20 | 0.54 |
| ▸ | HTR7 | P34969 | 2/20 | 0.54 |
| ▸ | HTR1D | P28221 | 1/20 | 0.54 |
| ▸ | HTR1B | P28222 | 1/20 | 0.54 |
| ▸ | HTR1F | P30939 | 1/20 | 0.54 |
| ▸ | DRD3 | P35462 | 1/20 | 0.54 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29651100 | 1.00 | HTR6 (0.64) | HTR6AKR1C3AKR1C1LMNASMN1; SMN2 | |
| SCHEMBL29460860 | 0.87 | KDM4E (0.68) | HTR6AKR1C3AKR1C1LMNASMN1; SMN2 | |
| SCHEMBL517434 | 0.87 | KDM4E (0.68) | HTR6AKR1C3AKR1C1LMNASMN1; SMN2 | |
| SCHEMBL9587637 | 0.85 | AKR1C3 (0.52) | HTR6AKR1C3AKR1C1CA12CA1 | |
| SCHEMBL19737423 | 0.85 | HTR6 (0.59) | HTR6AKR1C3AKR1C1LMNASMN1; SMN2 | |
| SCHEMBL4334765 | 0.85 | HTR6 (0.52) | HTR6AKR1C3AKR1C1LMNASMN1; SMN2 | |
| SCHEMBL1015250 | 0.85 | HTR6 (0.58) | HTR6AKR1C3AKR1C1LMNASMN1; SMN2 | |
| SCHEMBL19737553 | 0.82 | HTR6 (0.49) | HTR6AKR1C3AKR1C1LMNASMN1; SMN2 | |
| SCHEMBL13051118 | 0.82 | HTR6 (0.52) | HTR6AKR1C3AKR1C1LMNASMN1; SMN2 | |
| SCHEMBL30974768 | 0.82 | HTR6 (0.59) | HTR6AKR1C3AKR1C1LMNASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 69 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12612424-B2 | HPK1 inhibitors and uses thereof | REGOR PHARMACEUTICALS, INC. (US) | 2026-04-28 | — | — | US | disclosed |
| US-20220389037-A1 | HPK1 INHIBITORS AND USES THEREOF | REGOR PHARMACEUTICALS, INC. | 2022-12-08 | — | — | US | disclosed |
| EP-3313530-B1 | 4,6-PYRIMIDINYLENE DERIVATIVES AND USES THEREOF | DANA FARBER CANCER INST INC (US) | 2022-10-05 | — | — | EP | disclosed |
| EP-2655382-B1 | ORGANOZINC COMPLEXES AND PROCESSES FOR MAKING AND USING THE SAME | UNIV MUENCHEN LUDWIG MAXIMILIANS (DE) | 2022-09-28 | — | — | EP | disclosed |
| CN-114555585-A | HPK1 inhibitors and uses thereof | 上海齐鲁锐格医药研发有限公司 | 2022-05-27 | — | — | CN | disclosed |
| US-20210315894-A9 | 4,6-PYRIMIDINYLENE DERIVATIVES AND USES THEREOF | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2021-10-14 | — | — | US | disclosed |
| CN-108586500-B | Zinc coordination complex and method for preparing organic zinc reagent | 慕尼黑路德维希马克西米利安斯大学 | 2021-06-25 | — | — | CN | disclosed |
| WO-2021000935-A1 | HPK1 INHIBITORS AND USES THEREOF | QILU REGOR THERAPEUTICS INC. (CN) | 2021-01-07 | — | — | WO | disclosed |
| US-20200338075-A1 | 4,6-PYRIMIDINYLENE DERIVATIVES AND USES THEREOF | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2020-10-29 | — | — | US | disclosed |
| US-10695346-B2 | 4,6-pyrimidinylene derivatives and uses thereof | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2020-06-30 | — | — | US | disclosed |
| US-20060189646-A1 | Glucocorticoid mimetics, methods of making them, pharmaceutical compositions, and uses thereof | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. (US) | 2006-08-24 | — | — | US | disclosed |
| WO-2006071609-A2 | GLUCOCORTICOID MIMETICS, METHODS OF MAKING THEM, PHARMACEUTICAL COMPOSITIONS, AND USES THEREOF | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. (US) | 2006-07-06 | — | — | WO | disclosed |
| US-20060100218-A1 | Phosphodiesterase 4; asthma, chronic obstructive pulmonary disease, Alzheimer's disease, diffuse large-cell B cell lymphoma, and chronic lymphocytic leukemia; 8-[3-(3,4-dimethoxy-phenyl)-pyrrolo[2,3-b]pyridine-1-sulfonyl]-quinoline | PLEXXIKON, INC. | 2006-05-11 | — | — | US | disclosed |
| WO-2006026754-A9 | BICYCLIC HETEROARYL PDE4B INHIBITORS | PLEXXIKON INC (US) | 2006-04-20 | — | — | WO | disclosed |
| US-20060058295-A1 | Novel compounds as pharmaceutical agents | ELI LILLY AND COMPANY (US) | 2006-03-16 | — | — | US | disclosed |
| WO-2006026754-A2 | BICYCLIC HETEROARYL PDE4B INHIBITORS | PLEXXIKON, INC. (US) | 2006-03-09 | — | — | WO | disclosed |
| US-5939446-A | HYPOTENSIVE AGENTS FROM ISOXAZOLESULFONAMIDES | BRISTOL-MYERS SQUIBB CO. (US) | 1999-08-17 | — | — | US | disclosed |
| US-5382670-A | Platelet activating factor antagonists | ABBOTT LABORATORIES (US) | 1995-01-17 | — | — | US | disclosed |
| EP-0499987-A1 | Platelet activating factor antagonists | ABBOTT LABORATORIES (US) | 1992-08-26 | — | — | EP | disclosed |
| US-5120749-A | Treatment of anaphylactic shock, respiratory distress syndrome, acute inflammation, delayed cellulosr immunity, parturtition, fetal lung maturation, and cellular differentiation | ABBOTT LABORATORIES (US) | 1992-06-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060100218-A1 | Phosphodiesterase 4; asthma, chronic obstructive pulmonary disease, Alzheimer's disease, diffuse large-cell B cell lymphoma, and chronic lymphocytic leukemia; 8-[3-(3,4-dimethoxy-phenyl)-pyrrolo[2,3-b]pyridine-1-sulfonyl]-quinoline | PDE4B, PDE4A, PDE4C | HTR6 2439/4885AKR1C3 3503/4885AKR1C1 2925/4885 |
| US-20200338075-A1 | 4,6-PYRIMIDINYLENE DERIVATIVES AND USES THEREOF | CDK3, CDK1, CDK14 | HTR6 4189/4885AKR1C3 2956/4885AKR1C1 3920/4885 |
| US-12612424-B2 | HPK1 inhibitors and uses thereof | NEK11, NEK1, CSNK1A1 | HTR6 951/4885AKR1C3 493/4885AKR1C1 471/4885 |
| US-20060058295-A1 | Novel compounds as pharmaceutical agents | TGFB1, TGFB2, TGFBR1 | HTR6 3455/4885AKR1C3 2710/4885AKR1C1 3005/4885 |
| US-20220389037-A1 | HPK1 INHIBITORS AND USES THEREOF | HIPK1, SIK1, PGK1 | HTR6 3459/4885AKR1C3 2520/4885AKR1C1 1716/4885 |
| US-10695346-B2 | 4,6-pyrimidinylene derivatives and uses thereof | CDK3, CDK1, CDK14 | HTR6 4189/4885AKR1C3 2956/4885AKR1C1 3920/4885 |
| US-20210315894-A9 | 4,6-PYRIMIDINYLENE DERIVATIVES AND USES THEREOF | CDK3, CDK1, CDK14 | HTR6 4189/4885AKR1C3 2956/4885AKR1C1 3920/4885 |
| US-20060189646-A1 | Glucocorticoid mimetics, methods of making them, pharmaceutical compositions, and uses thereof | NR3C1, NR3C2, MC2R | HTR6 788/4885AKR1C3 87/4885AKR1C1 339/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.